More News! 6 Feb 2019 British Biotech Spin-Offs Get €40M Funding to Treat Narcolepsy Orexia and Inexia, two new virtual companies spun out of Sosei Heptares, will develop drugs for neurological diseases such as narcolepsy with funding from Medicxi Ventures. The companies will develop… February 6, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 30 Sep 2019 Taking Your Product Forward Against All Odds Having to let go of your flagship product after years of development is not easy. Nor is fundraising for another product after a major partner backs out — a challenge… September 30, 2019 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2017 British Researchers Find Thought Police to Treat Neurological Disorders Cambridge University scientists have identified a chemical in the brain that blocks unwanted thoughts, offering a new avenue to treat neurological disorders. Researchers at the University of Cambridge have found… November 7, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2020 UK Launches Clinical Trial Platform to Speed up Covid-19 Drug Development Researchers in the UK have set up a drug testing platform to bridge the gap between preclinical testing and large-scale trials for drugs being tested to treat Covid-19. The AGILE… July 7, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2023 Funding for university to develop new motor neuron disease therapies Medical research charity LifeArc, the Motor Neurone Disease Association (MND Association) and the My Name’5 Doddie Foundation have jointly awarded £1 million ($1.2 million) to researchers at University College London… January 24, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2018 Precision Antibiotic Improves Outcome of Gut Infections in Phase II Summit Therapeutics obtained Phase II results showing its antibiotic for C. difficile infections was more effective in reducing the recurrence of the disease than the standard of care. Clostridium difficile… August 3, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2022 Duke Street Bio enters stage with next-generation cancer therapies The UK startup Duke Street Bio has exited stealth mode with funding to develop PARP enzyme inhibitors that treat cancer by blocking the repair of DNA in tumor cells. London-based… May 25, 2022 - 3 minutesmins - By Susannah Rodgers Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 AI program yields multiple novel RSV drug targets Poolbeg Pharma says it has made a breakthrough in its Artificial Intelligence (AI) program with partner OneThree Biotech, Inc. through the discovery of novel drug targets for the treatment of… November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 9 May 2017 Scottish Shark Antibodies have caught Amgen’s Eye Elasmogen and its partner Feldan Therapeutics have signed a research agreement with Amgen to develop shark-inspired antibodies delivered intracellularly. Elasmogen, based in Aberdeen, Scotland, develops soloMER‘s, which are the smallest… May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2018 GW Pharma’s Latest Cannabinoid Drug Pegged Back by a Placebo in Phase II One of GW Pharma’s cannabinoid drugs for epilepsy has suffered a set back in a Phase IIa trial as a placebo matched its capacity to reduce the frequency of focal… February 22, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Nov 2018 Genentech and Immunocore Expand Partnership to Develop Cancer Immunotherapy Immunocore and the US biotech giant Genentech are building on their existing partnership to boost the clinical development of Immunocore’s immunotherapy for treating solid tumors. In the agreement, Genentech, a… November 20, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2019 GammaDelta Therapeutics Spins Out Cancer Immunotherapy Biotech The UK biotech GammaDelta Therapeutics has founded Adaptate Biotherapeutics to develop cancer immunotherapies based on antibodies that boost a rare type of immune cell. Adaptate Biotherapeutics is a spin-out of… October 16, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email